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The mechanisms involved in the uncommon resistance phenotype, carbapenem resistance
and  broad-spectrum cephalosporin susceptibility, were investigated in 25 Pseudomonas aeru-
ginosa clinical isolates that exhibited this phenotype, which were recovered from three
different hospitals located in São Paulo, Brazil. The antimicrobial susceptibility proﬁle was
determined by CLSI broth microdilution. -lactamase-encoding genes were investigated by
PCR  followed by DNA sequencing. Carbapenem hydrolysis activity was investigated by spec-
trophotometer and MALDI-TOF assays. The mRNA transcription level of oprD was assessed
by  qRT-PCR and the outer membrane proteins proﬁle was evaluated by SDS-PAGE. Genetic
relationship among P. aeruginosa isolates was assessed by PFGE. Carbapenems hydrolysis
was not detected by carbapenemase assay in the carbapenem-resistant and cephalosporin-
susceptible P. aueruginosa clinical isolates. OprD decreased expression was observed in all
P.  aeruginosa isolates by qRT-PCR. The outer membrane protein proﬁle by SDS-PAGE sug-
gested a change in the expression of the 46 kDa porin that could correspond to OprD porin.
The  isolates were clustered into 17 genotypes without predominance of a speciﬁc PFGE
pattern. These results emphasize the involvement of multiple chromosomal mechanisms
in  carbapenem-resistance among clinical isolates of P. aeruginosa, alert for adaptation of P.
aeruginosa clinical isolates under antimicrobial selective pressure and make aware of theemergence of an uncommon phenotype among P. aeruginosa clinical isolates.
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Introduction
Pseudomonas aeruginosa is one of the most frequent pathogens
associated to nosocomial infections, especially among
immunocompromised patients1 and exhibits notorious ver-
satility and capacity to acquire resistance mechanisms to
antimicrobial therapy.2 Beta-lactam antimicrobial agents
are the main option to treat serious infection caused by
this pathogen. However, the production of -lactamases,
such as cephalosporinases and carbapenemases, has been
intensely reported among clinical isolates of P. aeruginosa
from Latin America and represents the most effective mecha-
nism of -lactams resistance reported among Gram-negative
worldwide.3
Since the carbapenems molecules are more  resistant to
hydrolysis activity by a great number of spread serine-
-lactamases, these drugs have a particular value in the
treatment of infections caused by cephalosporinases pro-
ducer strains,4 which remain susceptible to carbapenems.
In P. aeruginosa,  the carbapenems resistance is modulated
by acquired carbapenemases in association with intrin-
sic mechanisms such as down-regulation or loss of OprD
porin, efﬂux pumps hyperexpression, chromosomal AmpC
-lactamase production, and target alterations.2,3 However,
since carbapenemases have the ability to hydrolyze peni-
cillins, cephalosporins, besides carbapenems, Gram-negative
bacteria carrying a carbapenemase-encoding gene frequently
exhibit resistance to virtually all -lactams.5
Given the importance of carbapenem for the treatment
of infections caused by P. aeruginosa,  it is essential to clarify
the mechanisms involved in unusual and/or poorly known
phenotypes. Knowledge of these mechanisms alert for an
adaptation to the selective pressure exerted by antimicrobial
and drug resistance development, thus affecting the treat-
ment of infections caused by these pathogens often restricted
to only polymyxins.
The aim of this study was to analyze the possible mecha-
nism of antimicrobial resistance involved in clinical isolates
of P. aeruginosa that exhibited an uncommon phenotype of
resistance: resistance to carbapenems but susceptibility to
broad-spectrum cephalosporins (Carb-R/Ceph-S).
Methods
Bacterial  isolates,  identiﬁcation  and  antimicrobial
susceptibility  testing
Between May, 2012 and March, 2013, a total of 25 P. aeru-
ginosa clinical isolates exhibiting carbapenem resistance but
broad-spectrum cephalosporin susceptibility (Carb-R/Ceph-
S) were recovered from 18 different infected patients from
three distinct hospitals located in São Paulo, Brazil (Table 1).
The identiﬁcation at the species level was conﬁrmed by
MALDI-TOF MS  in a Bruker Daltonics Microﬂex LT MALDI-
TOF using the Biotyper MALDI 2.0 (Bruker Daltonics, Bremen,
6Please cite this article in press as: Campana EH, et al. Carbapenem-resis
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Germany) as previously described. The susceptibility pro-
ﬁle was conﬁrmed by broth microdilution to imipenem,
meropenem, ceftazidime, cefepime, amikacin, gentamicin,
and ciproﬂoxacin according the CLSI recommendations.7,8 6;x x x(x x):xxx–xxx
American Type Culture Collection (ATCC) Escherichia coli ATCC
25922, P. aeruginosa ATCC 27853, and Staphylococcus aureus
ATCC 29213 strains were used as susceptibility testing quality
control.
ˇ-Lactamases-encoding  genes  detection  by  PCR  and  DNA
sequencing
Acquired -lactamases encoding genes were investigated
by PCR and DNA sequencing, as previously described,
using primers for: cephalosporinases (blaAmpC); (b) serino-
-lactamases (blaTEM, blaSHV, blaGES, blaCTX-M, blaBES, blaPER,
blaKPC, blaSME); (c) oxacillinases (blaOXA-1, blaOXA-2, blaOXA-3,
blaOXA-5, blaOXA-7, blaOXA-18, blaOXA-45, blaOXA-46, blaOXA-50,
blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58, blaOXA-20, blaOXA-48,
blaOXA-62, blaOXA-143, blaOXA-198); (d) metallo--lactamases
(blaIMP, blaVIM, blaSPM, blaGIM, blaSIM, blaNDM); and (e) class 1
integron.9 Amplicons were puriﬁed with the QIAquick PCR
puriﬁcation kit (Qiagen, Hilden, Germany) and sequenced
in both strands using the Applied Biosystems 3500 genetic
analyzer equipment (Applied Biosystems, PerkinElmer, USA).
The nucleotide sequence and the respective deduced amino
acid sequences were analyzed using the Lasergene software
package (DNAStar, Madison, WI,  USA) and compared with
the sequences available on the Internet using the BLAST tool
(http://www.ncbi.nlm.nih.gov/blast/).
Carbapenemase  hydrolysis  assay
Carbapenemase activity was investigated in bacterial cell
crude extracts by UV spectrophotometric assays against
100 M imipenem and 100 M meropenem in 100 mM phos-
phate buffer (pH 7.0), as previously described.10 In parallel,
carbapenem hydrolysis inhibition was performed by incubat-
ing the whole-protein extract with 25 mM EDTA for 15 min,
previously to the assay with imipenem and meropenem.
Imipenem hydrolysis was also investigated by MALDI-TOF
MS according to the method described by Carvalhaes and
colleagues.11
Relative  gene  transcriptional  level
Relative transcriptional levels of mexB, mexD, mexF, mexY,
ampC, and oprD were determined and analyzed with Real
Time 7500 (Applied Biosystems, Warrington, United King-
dom) as previously described.12 Quantitative RT-PCR was
performed with Platinum SYBR Green Supermix (Invitro-
gen, Carlsbad, USA). According to previous studies, reduced
oprD and increased ampC transcription levels were consid-
ered signiﬁcant when it was ≤70% and ≥10-fold, respectively,
compared to their transcriptional levels in PAO1 strain.13
MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY efﬂux
systems were considered overexpressed when mexB, mexC,
mexE, and mexY transcriptional level were at least 2-, 100-, 100-,
and 4-fold higher than those in PAO1 strain, respectively.14tant and cephalosporin-susceptible: a worrisome phenotype among
tp://dx.doi.org/10.1016/j.bjid.2016.10.008
Assessment  of  the  OMP  proﬁle  and  oprD  analysis
Ampliﬁcation of oprD gene was carried out by conventional
PCR as previously described15 and the amplicon size analyzed
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Table 1 – Carb-R/Ceph-S P. aeruginosa clinical isolates according to the hospital, susceptibility proﬁle, and oprD relative transcriptional level.
Strain ID Patient’s initial Isolation data Site of infection Hospital ID PFGE (Tenover) MIC (g/mL)b qRT-PCRc
IMI MER CAZ CEP AMI GEN CIP oprD
P01 J.A.N. May 7, 12 Tracheal aspirate H1 A 8 2 2 2 2 1 0.125 0.50
P02 J.A.O. Jun 13, 12 Tracheal aspirate H1 B 8 8 4 8 4 2 0.5 0.43
P03 J.D.T. Set 9, 12 Urine H1 C 8 2 2 8 8 4 32 0.41
P04 A.E. Jun 4, 12 Tracheal aspirate H2 D 16 4 8 8 8 4 0.25 0.10
P05 A.C.C. Jan 28, 13 Catheter tip H3 E 8 4 8 8 4 2 0.25 0.01
P06 A.C.C. Jan 28, 13 Catheter tip H3 F 8 8 8 8 8 4 0.5 0.18
P07 M.R.V. Jan 28, 13 Urine H3 G 8 4 8 8 4 2 0.5 0.02
P08 C.S.S. Jan 31, 13 Bloodstream H3 H 16 4 4 8 8 4 0.5 0.25
P09 A.C.C. Feb 4, 13 Catheter tip H3 E 16 8 2 4 4 2 0.25 0.07
P10 I.R. Feb 7, 13 Urine H3 L 8 2 2 4 4 2 0.125 0.37
P11 V.A.B. Feb 8, 13 Tracheal aspirate H3 I 8 8 1 2 2 2 0.125 0.19
P12 V.A.B. Feb 8, 13 Tracheal aspirate H3 I1 8 8 8 16 4 2 0.125 0.07
P13 A.C.L. Feb 9, 13 Respiratory tract H3 J 8 4 4 2 1 0.5 0.5 0.19
P14 V.A.B. Feb 17, 13 Tracheal aspirate H3 I2 8 4 2 2 2 2 0.125 0.08
P15 D.G.O. Feb 19, 13 Tracheal aspirate H3 M 8 1 1 8 8 4 16 0.01
P16 B.S. Feb 19, 13 Tracheal aspirate H3 F1 16 8 4 8 8 4 0.5 0.14
P17 B.S. Feb 21, 13 Respiratory tract H3 F1 8 8 4 16 8 4 1 0.13
P18 SNa Feb 24, 13 Urine H3 N 8 4 1 2 >128 >64 16 0.26
P19 A.R.P.G Feb 24, 13 Tracheal aspirate H3 O 16 4 4 8 2 16 16 0.50
P20 C.S.F. Feb 25, 13 Tracheal aspirate H3 P 8 2 2 8 8 4 0.5 0.13
P21 A.C.L. Feb 1, 13 Tracheal aspirate H3 K 16 8 2 4 1 1 0.25 0.25
P22 D.S.L. Mar 1, 13 Catheter tip H3 K 16 16 8 8 4 2 0.5 0.10
P23 A.J. Mar 2, 13 Urine H3 F1 8 4 4 4 16 0.5 8 0.01
P24 M.J.S. Mar 11, 13 Tracheal aspirate H3 F1 16 16 4 8 4 1 0.5 0.14
P25 SN D.R.C.a Mar 13, 13 Bloodstream H3 Q 16 16 2 8 4 2 0.25 0.47
a Newborn; unnamed (SN).
b Broth microdilution according to CLSI (2012, 2015). IMI, imipenem; MER, meropenem; CAZ, ceftazidime; CEP, cefepime; AMI, amikacin; GEN, gentamicin; CIP, ciproﬂoxacin.
c Relative transcriptional level of oprD gene compared to PA01 as reference strain.
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Fig. 1 – Outer membrane pattern of Carb-R/Ceph-S P. aeruginosa clinical isolates. Outer membrane proﬁles were  analyzed for
the presence of the porin, OprD. PAO1* and ATCC 27853a were  included as controls. The OprD and OprF protein bands are
(kDaindicated with arrow. MW,  molecular weight protein maker 
by 1.5% agarose gel electrophoresis. The outer membrane
proteins (OMP) were analyzed by SDS-PAGE in a 15% acryla-
mide and 0.3% N,N′-methylenebisacrylamide running gel. The
proteins were stained with coomassie blue r250 and photo-
graphed using GelDoc System Imaging. P. aeruginosa PA01 and
ATCC 27853 were used as reference strains.16
Molecular  typing  by  pulsed-ﬁeld  gel  electrophoresis
Genomic DNA of isolates was directly prepared from a bac-
terial cell suspension into agarose blocks and digested with
SpeI restriction enzyme (New England, Beverly, MA, USA). Elec-
trophoresis was performed on CHEF-DR III (BioRad, Richmond,
CA). The band patterns were analyzed by BioNumerics 2.0 soft-
ware  (Applied Maths, Belgium)17,18 and according to Tenover
interpretive criteria.19
Results
Carbapenem-resistance  not  related  to  carbapenemase
The decreased susceptibility to at least one tested car-
bapenem was conﬁrmed as well as the susceptibility to tested
cephalosporins as shown in Table 1. All evaluated isolates
exhibited resistance to imipenem with MIC  range varying from
8 to 16 g/mL. Although ﬁve isolates (20%) showed meropenem
susceptibility (MIC ≤ 2), most isolates had reduced suscepti-
bility to this antimicrobial (MICs ≥ 4 g/mL). All P. aeruginosa
isolates were susceptible to ceftazidime (MIC ≤ 8). Only two
isolates exhibited a cefepime MIC  equal to 16 g/mL, and were
classiﬁed as intermediate resistant to cefepime according CLSI
breakpoints.8
All 25 P. aeruginosa isolates carried the constitutive blaOXA-50
gene showing several DNA silent mutations but all of them
presented the predicted STYK motif commonly found in
class D -lactamases (DBLs), which have narrow -lactamase
hydrolysis activity.20 A single isolate (P18) also had posi-
tive PCR for blaOXA-56 gene. DNA sequencing analysis of the
blaOXA-56 genetic context showed that it was carried by a class
1 integron (named In163) as previously described by Carvalho
et al. among SPM-1 producing P. aeruginosa clinical isolates.21Please cite this article in press as: Campana EH, et al. Carbapenem-resis
Pseudomonas aeruginosa clinical isolates in Brazil. Braz J Infect Dis. 2016. ht
None tested carbapenemase encoding genes were detected by
PCR.
To determine whether the carbapenem-resistance was
mediated by an unknown carbapenemase, in vitro hydrolysis).
of imipenem and meropenem by whole-protein crude cell
extract was investigated by spectrophotometric and MALDI-
TOF MS analysis. None of the tested clinical sample were
able to hydrolyze imipenem and meropenem molecules in a
spectrophotometric assay (data not shown). Furthermore, no
carbapenem hydrolysis was detected by MALDI-TOF MS.
Mechanism  associated  with  carbapenem-resistance
The expression of OprD was estimated by mRNA transcriptio-
nal level by qRT-PCR and outer membrane protein pattern by
SDS-PAGE. Amplicons with size higher than expected for wild
type P. aeruginosa were observed for P05, P09, P13, P15, and P21
isolates. The ampliﬁcation of oprD gene failed in two  isolates
(P07 and P22). Relative transcriptional level was performed to
evaluate oprD down-regulation. Relative transcriptional level
analysis using P. aeruginosa PA01 as reference stain (baseline)
showed that the transcriptional level of oprD gene among
those isolates was signiﬁcantly reduced when compared to
wild-type PA01 strain.
The evaluation of the OMP by SDS-PAGE strongly suggested
that OprD was visually absent or produced at very low levels
by all isolates (Fig. 1).
Overall, the mRNA  transcription levels of mexB, mexC, mexE,
mexY and also of the -lactamase AmpC of most Carb-R/Ceph-
S P. aeruginosa isolates were even lower than those observed
for PAO1 strain (data not shown).
Genetic  relationship
High clonal diversity was observed between the 25 tested clin-
ical isolates of P. aeruginosa,  with 17 different PFGE patterns
without predominance of a single pattern (Fig. 2).
Discussion
Carbapenems have been extremely prescribed for treatment
of P. aeruginosa infections.2 Carbapenemase production has
emerged as the main mechanism of carbapenem resistance
among clinical isolates of P. aeruginosa.  However, loss of OprD
has also contributed for carbapenem resistance, especiallytant and cephalosporin-susceptible: a worrisome phenotype among
tp://dx.doi.org/10.1016/j.bjid.2016.10.008
conferring resistance to imipenem. Acquisition of mutations,
insertions, and/or deletions in the oprD gene are the most
common mechanisms of OprD inactivation as well as down-
regulation of oprD transcription.22
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Fig. 2 – Dendrogram showing the genotypic proﬁle of
Carb-R/Ceph-S P. aeruginosa clinical isolates determined by
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This study evaluated clinical isolates of P. aeruginosa
xhibiting reduced susceptibility to carbapenems not related
o carbapenemase production, which has been mostly related
o carbapenemase in Brazilian clinical settings.12,23 The emer-
ence of P. aeruginosa resistant to carbapenems associated
ith loss of porin has been documented in clinical settings
nd also could be selected in vitro after laboratory carbapen-
ms  exposure. In a study carried out by Fowler and colleagues,
hich evaluated the mechanism of carbapenems resistance
n selected mutants after exposure of a cystic ﬁbrosis clin-
cal isolate to sub-inhibitory concentration of meropenem,
emonstrated that loss of OprD by an IS element (ISPa8)  dis-
uption increased the MIC  to imipenem and meropenem from
.5 and 2 g/mL, respectively, to up to 16 g/mL.24 In another
ork conducted by Ocampo-Sosa and colleagues, OprD mod-
ﬁcations were also found among carbapenem susceptible
solates, with imipenem MICs varying from 0.06 to 4 g/mL in
 clinical setting of metallo--lactamase-negative P. aeruginosa
solated from Spanish hospitals.16Please cite this article in press as: Campana EH, et al. Carbapenem-resist
Pseudomonas aeruginosa clinical isolates in Brazil. Braz J Infect Dis. 2016. ht
In the present study we  analyzed P. aeruginosa isolates
esistant to at least one carbapenem with imipenem MICs
anging from 8 to 16 g/mL and meropenem MIC varying from;x  x x(x x):xxx–xxx 5
1 to 16 g/mL that remained susceptible to broad-spectrum
cephalosporins. All isolates analyzed had a signiﬁcant reduced
expression or lack of OprD porin in P. aeruginosa outer mem-
brane by expression of a null or altered oprD gene.
We found a high diversity of genotypes among the
OprD-deﬁcient P. aeruginosa,  which were isolated from three
different hospitals located in São Paulo city, Brazil. It may
reveal an emergence of OprD-deﬁcient P. aeruginosa in
the Brazilian clinical scenario by a manner independently
of a clone spread outwards, in accordance with previ-
ous observation.25 The ability of OprD-mutant selection by
carbapenems exposure may play an important role to OprD-
mutant emergence and it should be considered regarding
empirical clinical usage of carbapenems.
Loss of OprD has also been implicated in an increased
in vivo ﬁtness and/or virulence in a murine infection model.
OprD-deﬁcient P. aeruginosa strains were more  resistant to
low pH environment, to normal human serum, and presented
an increased cytotoxicity against murine macrophages. It has
suggested that the association of antimicrobial resistance and
increased survival of these strains can favor the permanence
of this strains in the hospital setting and make treatment
more difﬁcult.26 The increase in OprD-deﬁcient survival can
also raise the persistence of these strains in the hospital envi-
ronment and favor the acquisition of new determinant of
antimicrobial resistance by horizontal gene transfer.27 It is
worth mentioning that all isolates evaluated in this study were
susceptible to broad-spectrum cephalosporins (ceftazidime
and cefepime). As previously demonstrated, OprD mutants
are resistant only to zwitterionic carbapenems, especially
imipenem and the cross-resistance to others -lactams has
not been observed in these strains. Carb-R/Ceph-S phenotype
might be used as a phenotypic biomarker for screening OprD-
deﬁcient P. aeruginosa clinical isolates. Since these P. aeruginosa
do not produce high levels of AmpC, theoretically ceftazidime
or cefepime could be prescribed for treatment of such infec-
tions. However, more  studies would be necessary to ensure
the efﬁcacy of broad-spectrum cephalosporins for treatment
of Carb-R/Ceph-S P. aeruginosa infections.
Conclusion
The carbapenem resistance of P. aeruginosa associated to
OprD-deﬁcient may become more  frequent in the hospitals
scenario as consequence of selective pressure exerted by clin-
ical use of carbapenems. Considering the therapeutic value of
carbapenems as one of the last options for the treatment of P.
aeruginosa infectious and the emergence of P. aeruginosa as a
public health problem, rational carbapenems usage is essen-
tial to reduce the selective pressure over P. aeruginosa clinical
isolates.
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